Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Tan-Chiu

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Oncology|November 8, 2002
Moving forward: Herceptin in the adjuvant settingElizabeth Tan-Chiu, Martine Piccart
Breast Cancer Research and Treatment|November 27, 2004
Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experienceSandra Franco, Alejandra Perez, Elizabeth Tan-Chiu, et al.
Journal of the National Cancer Institute|April 22, 2004
Lower-category benign breast disease and the risk of invasive breast cancerJiping Wang, Joseph P Costantino, Elizabeth Tan-Chiu, et al.
Journal of the National Cancer Institute|February 20, 2003
Effects of tamoxifen on benign breast disease in women at high risk for breast cancerElizabeth Tan-Chiu, Jiping Wang, Joseph P Costantino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trialsIrene L Wapnir, Stewart J Anderson, Eleftherios P Mamounas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancerAdam Brufsky, W Graydon Harker, J Thaddeus Beck, et al.
Breast Cancer Research and Treatment|November 18, 2006
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancerHope Rugo, Emma Shtivelman, Alejandra Perez, et al.
Journal of the National Cancer Institute|June 6, 2002
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experienceSoonmyung Paik, John Bryant, Elizabeth Tan-Chiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2011
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHERAdam M Brufsky, Musa Mayer, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Oncology|November 8, 2002
Moving forward: Herceptin in the adjuvant settingElizabeth Tan-Chiu, Martine Piccart
Breast Cancer Research and Treatment|November 27, 2004
Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experienceSandra Franco, Alejandra Perez, Elizabeth Tan-Chiu, et al.
Journal of the National Cancer Institute|April 22, 2004
Lower-category benign breast disease and the risk of invasive breast cancerJiping Wang, Joseph P Costantino, Elizabeth Tan-Chiu, et al.
Journal of the National Cancer Institute|February 20, 2003
Effects of tamoxifen on benign breast disease in women at high risk for breast cancerElizabeth Tan-Chiu, Jiping Wang, Joseph P Costantino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trialsIrene L Wapnir, Stewart J Anderson, Eleftherios P Mamounas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancerAdam Brufsky, W Graydon Harker, J Thaddeus Beck, et al.
Breast Cancer Research and Treatment|November 18, 2006
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancerHope Rugo, Emma Shtivelman, Alejandra Perez, et al.
Journal of the National Cancer Institute|June 6, 2002
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experienceSoonmyung Paik, John Bryant, Elizabeth Tan-Chiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2011
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHERAdam M Brufsky, Musa Mayer, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.
Pageof 2